Market Overview

UPDATE: Jefferies Raises PT on Pfizer on Attractive Valuation

Share:
Related PFE
Mike Khouw Sees Unusual Options Activity In Pfizer
S&P 500 Index Futures Trading Lower
Despite Recent Downgrade, This Ecommerce Giant is a Buy (GuruFocus)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Pfizer (NYSE: PFE), and raised the price target from $31.00 to $33.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Pfizer closed on Tuesday at $29.11.

Latest Ratings for PFE

DateFirmActionFromTo
Jun 2015Piper JaffrayInitiates Coverage onOverweight
Jun 2015JefferiesInitiates Coverage onOverweight
Apr 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

Around the Web, We're Loving...

Get Benzinga's Newsletters